‘Sleeping blockbuster’: MPM leads $53M Series E for Antiva as biotech seeks second go at tackling HPV

Kyle LaHucik

Senior Reporter

Antiva Biosciences has picked up another $53 million to bankroll two key studies of its topical drug for high-risk HPV infections and pre-cancerous lesions. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘Sleeping blockbuster’: MPM leads $53M Series E for Antiva as biotech seeks second go at tackling HPV

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Roche CEO warns that tariffs could impact dealmaking

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

‘Sleep­ing block­buster’: MPM leads $53M Se­ries E for An­ti­va as biotech seeks sec­ond go at tack­ling HPV

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Bris­tol My­ers CEO sig­nals deal­mak­ing will be a top pri­or­i­ty in 2025

Drug­mak­ers see a sub­stan­tial, but man­age­able, hit to busi­ness from tar­iffs. But the worst may lie ahead

Roche CEO warns that tar­iffs could im­pact deal­mak­ing

Roche takes steps to pro­tect it­self from tar­iffs, while Sanofi hangs back

Ther­mo Fish­er buck­les up for US-Chi­na trade war, bud­gets $2B to ease im­pact

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

‘Sleeping blockbuster’: MPM leads $53M Series E for Antiva as biotech seeks second go at tackling HPV

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Roche CEO warns that tariffs could impact dealmaking

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence